Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 5,923 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Peanut Allergy
Interventions: AR101 - Peanut protein capsule; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Periodontal Diseases, Diabetes, Osteoporosis, Cardiovascular Risk Factor
Interventions: Disease status; Other
Lead sponsor: Tufts University; Other
Eligibility: 45 Years to 100 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Solid Tumor
Interventions: BDTX-189; Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more

Conditions: Colorectal Cancer
Interventions: DJ-927; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Houston, Texas

Conditions: Ulcerative Colitis
Interventions: tofacitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more

Conditions: Oral Leukoplakia
Interventions: Pioglitazone hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Sinusitis
Interventions: Zithromax (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology, Blood sampling for plasma chemistry profile, Serum pregnancy test (for women of child-bearing potential); Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more

Conditions: Atrial Fibrillation, AFib
Interventions: AtriClip LAA Exclusion Device; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Interventions: CB-839, CB-Aza; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: bosentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more

Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions: erlotinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Preterm Birth
Interventions: oral micronized progesterone, Identical Placebo tablet; Drug
Lead sponsor: Fetal Medicine Foundation; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: HIV Infection
Interventions: Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Trigeminal Neuralgia
Interventions: Olive oil and Dietary Guideline recommendations, Dietary Guideline recommendations; Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: fluorouracil, eniluracil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye
Interventions: ECF843, ECF843 vehicle; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 52
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more

Conditions: Acne Vulgaris, Isotretinoin
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 6
States / cities: Concord, North Carolina • Davidson, North Carolina • Harrisburg, North Carolina + 2 more

Conditions: Epilepsy, Partial
Interventions: Levetiracetam, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Schizophrenia
Interventions: AZD0328, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Garden Grove, California • Glendale, California

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 43
States / cities: Los Angeles, California • Riverside, California • Santa Monica, California + 38 more

Conditions: Cancer, Breakthrough Pain
Interventions: ACTIQ®; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 3 Years to 15 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 30
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more

Search by objective public record fields.

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Genomic Determinants and Shared Genetic Pathways of Periodontal Disease

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Pioglitazone for Oral Premalignant Lesions

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

Stroke Feasibility Study

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Oral Progesterone for Prevention of Preterm Birth

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia

Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)